Progressive Central Nervous System Metastases in Responder Patients for Outside Central Nervous System Metastases on Trastuzumab-Based Therapy : Report of Two Cases of Refractory Breast Cancer

アクセス数 : 950
ダウンロード数 : 111

今月のアクセス数 : 5
今月のダウンロード数 : 1
File
KJ00004161813.pdf 399 KB 種類 : fulltext
Title ( eng )
Progressive Central Nervous System Metastases in Responder Patients for Outside Central Nervous System Metastases on Trastuzumab-Based Therapy : Report of Two Cases of Refractory Breast Cancer
Creator
Okita Riki
Saeki Toshiaki
Takashima Shigemitsu
Aogi Kenjiro
Ohsumi Shozo
Source Title
Hiroshima Journal of Medical Sciences
Volume 54
Issue 1
Start Page 35
End Page 38
Journal Identifire
[PISSN] 0018-2052
[EISSN] 2433-7668
[NCID] AA00664312
Abstract
We report two cases of central nervous system (CNS) metastases during systemic response to trastuzumab in combination with chemotherapy for refractory breast cancer. The patients responded to trastuzumab in combination with chemotherapy. During combination treatment, the patients developed cerebellar metastases. A follow-up computed tomography scan revealed that their diseases continued to respond outside the CNS. These cases suggest that the failure of trastuzumab to cross the blood-brain barrier may compromise its overall effectiveness and raises the possibility that CNS metastasis may become clinically more significant in patients receiving antibody-based therapies, including patients responding to therapy outside the CNS. Additionally, repeated stereotactic radiosurgery as gammaknife combination therapy synchronously with systematic trastuzumab-based therapy was useful for the treatment of metastatic breast carcinoma.
Keywords
Breast cancer
Trastuzumab
Stereotactic radiosurgery (SRS)
Central nervous system (CNS) metastasis
NDC
Medical sciences [ 490 ]
Language
eng
Resource Type departmental bulletin paper
Publisher
Hiroshima University Medical Press
国立情報学研究所
Date of Issued 2005-03
Publish Type Version of Record
Access Rights open access
Source Identifier
[ISSN] 0018-2052
[NCID] AA00664312